glossary

How practical it is for people to receive a treatment, including where and how it can be delivered, how it needs to be stored and transported, and the healthcare infrastructure required to provide it.

The ability for a cancer treatment to be provided at a cost that enables more people to access it without placing a financial burden on patients and their families.

An earlier-generation Kode Immuno-Educer evaluated in a Phase 1/2a human clinical study.

Human clinical experience with AGI-134 contributes to the scientific foundation supporting K5K.

Read more →

The ability of a treatment to remain stable without continuous refrigerated storage.

This can make storage and transportation easier, particularly in rural, remote and lower-resource settings where cold-chain infrastructure may be limited.

A type of cancer treatment that uses or stimulates the body's immune system to recognise and attack cancer.

The process of evaluating and advancing a potential treatment through clinical studies in people to understand its safety, how it behaves and whether it may provide benefit.

A carefully designed study involving people that evaluates a potential treatment, including its safety and how it works.

Temperature-controlled storage and transportation used to keep some medicines within a required temperature range from manufacture through to use.

Treatments that require less reliance on cold-chain infrastructure can be easier to store and transport in some healthcare settings.

Recognising that people face different circumstances and barriers, and creating greater opportunities for them to benefit according to their needs.

In cancer treatment, this includes considering barriers such as cost, where people live and access to healthcare.

Creating greater opportunities for people to access cancer treatment regardless of where they live or their financial circumstances.

The way Equitable Oncology helps advance cancer treatments with the people who may ultimately need them in mind from the beginning.

The Model brings together scientific innovation, philanthropy and collaborative partnerships while considering factors such as cost, manufacturing, storage and how and where treatment could ultimately be delivered.

Read more →

An organisation or individual invited to work collaboratively with Equitable Oncology where their expertise, capability, infrastructure or resources can contribute to our programmes and charitable purpose.

Equitable Oncology Partners remain independent, and participation is by invitation.

Read more →

An independent organisation or professional engaged to provide specialist expertise or services that Equitable Oncology needs to deliver its work.

Equitable Oncology Service Providers work with us through agreed contractual arrangements while remaining independent.

Read more →

An individual or organisation that chooses to support Equitable Oncology's charitable purpose through philanthropy, financial contributions, resources, advocacy, connections or other forms of support.

Equitable Oncology Supporters remain independent and can contribute in ways that reflect their interests and capabilities.

Read more →

The first stage in which a new treatment is evaluated in people to begin assessing its safety and how it behaves in the human body.

Equitable Oncology's approach to using philanthropy to help fund the advancement of cancer treatments.

By reducing the amount that needs to be recovered through the eventual treatment price, philanthropic funding can help create greater opportunities for more people to benefit.

Where Equitable Oncology shares in the success it helps create, any returns can be used to support future programmes and further our charitable purpose.

Legal rights associated with inventions, discoveries, technologies and other creations.

Intellectual property ownership will depend on the individual programme. For K5K, the treatment is owned and developed by KodeRx Limited, while the underlying Kode Immuno-Educer (KIE) technology platform is owned and developed by Kode Biotech Limited.

K5K is an innovative cancer immunotherapy and the first programme being advanced through the Equitable Oncology Model.

The name K5K reflects:

• K – Kode Technology, the platform on which K5K is based.
• 5 – its target treatment cost of USD $5,000 or less per treatment course.
• K – thousand, reflecting the target cost of USD $5,000 (5K) per treatment course.

Read more →

A technology designed to tag cancer cells with immune-stimulating markers, helping make the cancer visible to the immune system so it can recognise and respond to it.

Read more →

A third-generation Kode Immuno-Educer is being evaluated in veterinary oncology and preliminary anti-tumour responses have been observed.

Kv9 uses the same molecule as K5K, providing translational evidence relevant to the K5K human programme.

Read more →

The area of medicine concerned with the diagnosis and treatment of cancer.

The voluntary contribution of money or other resources to support a charitable or public-benefit purpose.

For Equitable Oncology, philanthropy helps fund our charitable work and the advancement of cancer treatment programmes.

The ability to manufacture a treatment efficiently and consistently in increasing quantities as more treatment is required.

A simple way of describing how K5K is designed to stimulate an immune response against cancer.

TAG: K5K tags cancer cells with immune-stimulating markers, helping make the cancer visible to the immune system.

ALARM: Immune cells are recruited to the K5K-treated tumour.

ATTACK: The activated immune system attacks the treated tumour and aims to generate a broader response against other tumours elsewhere in the body.

Read more →

Evidence from one area of research or clinical experience that helps inform the development of a treatment in another setting.

For K5K, this includes relevant clinical experience from treating cancer in animals with Kv9.

Read more →